尔康制药：上半年归母净利润同比增长497.36%

Core Viewpoint - Erkang Pharmaceutical reported a revenue of 682 million yuan for the first half of 2025, reflecting a year-on-year growth of 9.74% and a net profit attributable to shareholders of 37.6346 million yuan, which represents a significant increase of 497.36% [1] Financial Performance - The company's revenue for the first half of 2025 reached 682 million yuan, marking a 9.74% increase compared to the previous year [1] - The net profit attributable to shareholders was 37.6346 million yuan, showing a remarkable growth of 497.36% year-on-year [1]